Poor
Not Aligned
Patient Risk:
Moderate
Summary
Most factual/quantitative claims (dosing range, LDL/HDL percentage changes, onset timing, and specific regulatory/patent counts) are not supported by the provided FDA label excerpts and cannot be verified against them; some interaction assertions are only partially aligned at a high level.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a statin medication.
Label 11 (DESCRIPTION): Atorvastatin is described as an HMG-CoA reductase inhibitor (statin class).
Lipitor is available in tablet strengths of 10 mg, 20 mg, 40 mg, or 80 mg.
Label 11 (DESCRIPTION): 'LIPITOR Tablets for oral administration contain 10, 20, 40, or 80 mg atorvastatin.'
Unsupported Statements
Lipitor is used to treat high cholesterol, including familial hypercholesterolemia.
The provided indication excerpt discusses adjunct therapy in individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia, but it does not mention familial hypercholesterolemia specifically.
A study in the Journal of Clinical Lipidology found Lipitor was more effective than simvastatin (Zocor) in reducing LDL cholesterol and improving lipid profiles.
No comparative efficacy study details or journal citation appear in the provided excerpts.
Lipitor (atorvastatin) reduces LDL cholesterol by 40% to 60%.
No LDL percentage reduction figures are provided in the supplied label excerpts.
Lipitor (atorvastatin) increases HDL cholesterol by 10% to 20%.
No HDL percentage increase figures are provided in the supplied label excerpts.
Lipitor is described as a very effective statin.
No qualitative phrasing such as 'very effective' is present in the provided label excerpts.
Lipitor has a patent expiration in 2011.
No patent/regulatory exclusivity or expiration date information is present in the provided label excerpts.
Generic versions of Lipitor were introduced after its patent expired.
No generic launch timing or patent expiry relationship is present in the provided label excerpts.
There are currently 15 generic versions of Lipitor available in the United States.
No count of generic products is present in the provided label excerpts.
Lipitor typically starts working within 4 to 6 weeks.
No onset-of-effect timeframe is provided in the supplied label excerpts.
Lipitor may take several months to achieve optimal results.
No timeframe for achieving 'optimal results' is provided in the supplied label excerpts.
Lipitor is generally safe for patients with kidney disease.
The provided excerpts only mention that a history of renal impairment may be a risk factor for rhabdomyolysis and warrants closer monitoring; they do not support a blanket statement of 'generally safe' in kidney disease.
Lipitor is available in generic form.
No information about availability of generic formulations is present in the provided label excerpts.
Lipitor is more potent than some other options, such as Zocor (simvastatin).
No comparative potency statement is present in the provided label excerpts.
Contradictions
Low
AI Statement
Lipitor is generally safe for patients with kidney disease.
Label Reference
Label 5.1 Skeletal Muscle: 'A history of renal impairment may be a risk factor for the development of rhabdomyolysis. Such patients merit closer monitoring for skeletal muscle effects.'
Important Omissions
For the interaction claim, the label excerpt specifies increased myopathy risk with particular drug classes/agents (e.g., fibric acid derivatives, lipid-modifying doses of niacin, cyclosporine, and strong CYP 3A4 inhibitors such as clarithromycin, HIV protease inhibitors, and itraconazole) and advises careful monitoring; the AI claim does not reflect these specifics.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported timing/efficacy quantification and an overgeneralized 'generally safe in kidney disease' statement conflict with the label’s caution about renal impairment as a rhabdomyolysis risk factor.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple claims are unsupported by the provided label excerpts (quantitative efficacy, onset timing, patent/generic counts) and one statement conflicts with label caution regarding renal impairment.
Suggested Improvement
Limit claims to what is explicitly supported by the provided excerpts (e.g., tablet strengths, high-level adjunct-to-diet use for hypercholesterolemia risk reduction, and specific drug-interaction risk with named strong CYP3A4 inhibitors/fibric acid/niacin/cyclosporine) and remove unsupported regulatory and quantitative efficacy/onset assertions.